The genomics industry has launched InGeNA, a new alliance to strengthen collaboration, coordinate on key issues and realise opportunities for all Australians to benefit from precision healthcare. The Industry Genomics Network Alliance has 13 founding member companies in healthcare and life sciences who will collaborate on programs to embed genomics across Australian healthcare.
The founding companies, from pathology, technology and biopharma sectors, contributed funding to start InGeNA matched by $300,000 from MTPConnect Industry Growth Centre, an Australian Government initiative supported by the Department of Industry, Science, Energy and Resources.
InGeNA will be hosted by the Australasian Institute of Digital Health and undertake a targeted program of work to address a range of genomics opportunities and challenges from screening and testing through to treatment. Projects include white papers, consultation and policy positions on key areas including access and equity, genetic screening, dynamic consent, workforce planning, and Australia’s adoption of new drugs and novel medical technologies.
The collaborating partners are:
- 23 Strands
- AbbVie
- Amgen
- Amicus
- Applied Precision Medicine
- Bristol Myers Squibb
- Illumina
- Janssen
- Qiagen
- Roche
- Sanofi
- Thermo Fisher
- TrakGene
InGeNA has appointed Institute Fellow and digital health leader David Bunker as the inaugural Chair. David established Queensland Genomics and is currently Executive Director of Brisbane Diamantina Health Partners (BDHP).
Find out more at www.ingena.org.au.